Winning AVXL Stock Forecast: Life Changing Treatment Discoveries and M&A Expectations Add Value to Avanex
“We are looking forward, focusing on executing clinical trials using the inclusion of advanced genomic biomarkers into late-stage CNS precision medicine trials, including our Rett syndrome, Alzheimer’s disease and Parkinson’s disease dementia trials – all indications with high unmet need”
-Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex.
Anavex Life Sciences Corp. (NASDAQ: AVXL) is a biopharmaceutical company focused on using genetic medicine to treat neurodegenerative and neurodevelopmental diseases, such as Alzheimer’s disease
